It has been a busy few months for Allergan, who can forget their historic merger at the end of 2015 with pharmaceutical giant Pfizer? The new year brings a breakthrough for Allergan, they have since announced that they will be buying Anterios Inc., a clinical-stage biopharmaceutical company that is currently developing what they refer to as “ a next-generation delivery system and a revolutionary breakthrough in botulinum toxin-based prescription products.”


So what does this actually mean for patients and practitioners? Allergan is one of the best-known and most trusted maker of botulinum toxin (Botox), a treatment that has become increasingly popular over the last decades due to it’s ability to erase the signs of ageing, effective treatment of hyperhidrosis amongst many other cosmetic and therapeutic uses. What makes the Allergan and Anterios Inc. merger so interesting is that Allergan will now be in business with a company that has a “proprietary platform delivery technology that enables local, targeted delivery of neurotoxins through the skin without the need for injections.” Put simply, it sounds like Anterios Inc. have created a topical type of Botox. Additionally, Allergan have also announced that they have acquired the global rights to Anterios’ Phase 2 programme ANT-1207, which is a botulinum toxin based topical lotion, with intended use for the treatment of hyperhidrosis, acne and wrinkle reduction. All the great results of Botox minus the dreaded injections?


In the official Allergan news release, Executive Vice President David Nicholson said the acquisition “demonstrates our ability to apply our tremendous scientific leadership in neurotoxins to further extend our already deep neurotoxin pipeline by advancing a new delivery system and formulations that are appealing to both patients and physicians.”


Here at Elanic we are delighted that our Botulinum toxin provider, Allergan, is once again showing their commitment to aesthetics by purchasing Anterios Inc. and acquiring the global rights to the revolutionary ANT-1207. We believe there is a fantastic amount of potential for such topical treatments, this new approach is openly welcomed by patients and practitioners looking for a non-invasive approach to treat aesthetic and dermatologic conditions. A less invasive treatment is likely to bring more people that are considering cosmetic procedures into the clinic, we find a lot prospective patients put off due to the injection.


To discus any cosmetic or dermatologic concerns you may have please get in touch and one of our highly trained and skilled practitioners will be more than happy to discuss your concerns further. You can fill in our online contact form and one of our team will be in touch to discuss your enquiry. Alternatively, you can call the clinic on 0800 334 5153 or 0141 332 5106. We look forward to hearing from you.